5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,6]naphthyridin-4-one | 374631-20-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,6]naphthyridin-4-one
• 英文别名: 5-Chloro-1-heptan-4-yl-7-methyl-2,3-dihydro-1,6-naphthyridin-4-one
• CAS: 374631-20-6
• 化学式: C₁₆H₂₃ClN₂O
• 分子量: 294.824
• InChiKey: NMAMFLWKAWPUOS-UHFFFAOYSA-N

物化性质

• 沸点：
  445.1±45.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,6]naphthyridin-4-one 在 potassium tert-butylate 、 对甲苯磺酸一水合物 作用下， 以 四氢呋喃 、 环丁砜 为溶剂， 反应 2.17h， 生成 1-(3-Isopropoxy-propyl)-7-methyl-5-(1-propyl-butyl)-1,3,4,5-tetrahydro-1,5,8-triaza-acenaphthylene
  参考文献：
  名称：

  Potent, Orally Active Corticotropin-Releasing Factor Receptor-1 Antagonists Containing a Tricyclic Pyrrolopyridine or Pyrazolopyridine Core

  摘要：

  Two new classes of tricyclic-based corticotropin-releasing factor (CRF1) receptor-1 antagonists were designed by constraining known 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine ligands. Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF1 receptor (K-i = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC50 = 14, 6.8 nM). These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V-D = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)). When given orally, both the pyrazole and the pyrrole leads dose-dependently inhibit stress-induced ACTH release in vivo. ACTH reductions of 84-86% were observed for 30 mg kg(-1) doses.

  DOI：

  10.1021/jm050070m
• 作为产物：
  描述：

  2,4-二氯-6-甲基吡啶-3-甲酸乙酯 在 lithium aluminium tetrahydride 、 四丙基高钌酸铵 、 草酰氯 、 4 A molecular sieve 、 二甲基亚砜 、 N-甲基吗啉氧化物 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 25.5h， 生成 5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,6]naphthyridin-4-one
  参考文献：
  名称：

  Potent, Orally Active Corticotropin-Releasing Factor Receptor-1 Antagonists Containing a Tricyclic Pyrrolopyridine or Pyrazolopyridine Core

  摘要：

  Two new classes of tricyclic-based corticotropin-releasing factor (CRF1) receptor-1 antagonists were designed by constraining known 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine ligands. Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF1 receptor (K-i = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC50 = 14, 6.8 nM). These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V-D = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)). When given orally, both the pyrazole and the pyrrole leads dose-dependently inhibit stress-induced ACTH release in vivo. ACTH reductions of 84-86% were observed for 30 mg kg(-1) doses.

  DOI：

  10.1021/jm050070m

文献信息

• Chemical compounds
  申请人：——

  公开号：US20040242623A1

  公开（公告）日：2004-12-02

  The present invention relates to tricyclic pyridines compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof: 1

  本发明涉及公式（I）的三环吡啶化合物，包括立体异构体、前药和其药学上可接受的盐或溶剂化物：1
• Tricyclic CRF receptor antagonists
  申请人：SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company

  公开号：EP1425281B1

  公开（公告）日：2006-02-01
• US7273871B2
  申请人：——

  公开号：US7273871B2

  公开（公告）日：2007-09-25
• Potent, Orally Active Corticotropin-Releasing Factor Receptor-1 Antagonists Containing a Tricyclic Pyrrolopyridine or Pyrazolopyridine Core
  作者：Brian Dyck、Dimitri E. Grigoriadis、Raymond S. Gross、Zhiqiang Guo、Mustapha Haddach、Dragan Marinkovic、James R. McCarthy、Manisha Moorjani、Collin F. Regan、John Saunders、Michael K. Schwaebe、Tomas Szabo、John P. Williams、Xiaohu Zhang、Haig Bozigian、Ta Kung Chen

  DOI：10.1021/jm050070m

  日期：2005.6.1

  Two new classes of tricyclic-based corticotropin-releasing factor (CRF1) receptor-1 antagonists were designed by constraining known 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine ligands. Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF1 receptor (K-i = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC50 = 14, 6.8 nM). These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V-D = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)). When given orally, both the pyrazole and the pyrrole leads dose-dependently inhibit stress-induced ACTH release in vivo. ACTH reductions of 84-86% were observed for 30 mg kg(-1) doses.